Cetuximab, its clinical use and future perspectives
Authors:
- Fernando RiveraFRFernando Rivera
- Maria Eugenia Vega-VillegasMVMaria Eugenia Vega-Villegas
- Marta Francisca López-BreaMLMarta Francisca López-Brea
- 1 February 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 19 (2) , 99-113
Abstract
Increase in the expression of epidermal growth factor receptors (EGFRs) has been observed in many tumours. EGFR overexpression usually correlates with a more advanced stage of the disease, a poorer prognosis and a worse chemotherapy response. For all the aforementioned reasons, EGFR inhibition can be considered an attractive approach in cancer treatment. One strategy has been extracellular domain receptor inhibition, using monoclonal antibodies. In this review, we summarize the current status as well as what is likely to be the future use of monoclonal antibodies directed against EGFR. We have focussed on cetuximab being the most developed one. It has been mainly studied in colorectal cancer, and the major portion of this review will focus on all the research that has been carried out on this tumour. Clinical development of cetuximab is also important in head and neck cancer and in lung cancer. Interesting studies have been carried out in pancreatic, gastric, oesophageal and ovarian tumours, as well as in malignant gliomas.Keywords
This publication has 53 references indexed in Scilit:
- Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast CancerJournal of Clinical Oncology, 2007
- EGFR Targeting of Solid TumorsCancer Control, 2007
- Her signaling in pancreatic cancerExpert Opinion on Biological Therapy, 2007
- Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127Journal of Clinical Oncology, 2006
- Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell CarcinomasJournal of Clinical Oncology, 2006
- Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapyEuropean Journal of Cancer, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Searching for Reliable Epidermal Growth Factor Receptor Response PredictorsClinical Cancer Research, 2004
- The protein tyrosine kinase family of the human genomeOncogene, 2000
- Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.Journal of Clinical Oncology, 1993